Advertisement
Screener

ImageneBio, Inc. (IMA) Graph

IMA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Revenue including tax (m); Research and development $6.67M; Operating expenses $11.78M.
  • 2026-03-31: Revenue (m); Revenue including tax (m); Research and development $5.96M; Operating expenses $12.08M.
  • 2025-12-31: Revenue $0.00*; Revenue including tax $0.00*; Research and development $3.27M*; Operating expenses $8.50M*.
  • 2025-09-30: Revenue (m); Revenue including tax $0.00; Research and development $15.56M; Operating expenses $26.59M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)(m)$6.67M$11.78M$16.00K-$10.18M
2026-03-31(m)(m)$5.96M$12.08M$10.00K-$10.62M
2025-12-31$0.00*$0.00*$3.27M*$8.50M*-$276.00K*-$6.91M*
2025-09-30(m)$0.00$15.56M$26.59M-$74.00K-$24.78M
2025-06-30(m)(m)$5.65M$7.36M$15.00K-$7.58M
2025-03-31$800.00K$800.00K$4.04M$6.79M$28.00K-$6.08M
2024-09-30$3.50M$3.50M$3.88M$5.54M$0.00-$3.18M
2024-06-30(m)(m)$9.83M$15.82M$62.00K-$6.26M
2024-03-31(m)(m)$9.64M$18.23M$27.00K-$22.31M
2023-09-30$1.19M(m)$14.65M$20.69M(m)-$17.34M
2023-06-30$2.00M(m)$15.17M$20.49M(m)-$17.11M
2023-03-31$5.31M(m)$15.55M$20.83M(m)-$14.22M
2022-09-30$6.40M(m)$18.85M$24.28M(m)-$17.34M
2022-06-30$382.00K(m)$15.49M$21.33M(m)-$20.49M
2022-03-31$3.38M(m)$14.34M$20.35M(m)-$16.84M
2021-09-30$3.75M(m)$13.38M$18.27M(m)-$14.52M
2021-06-30$3.55M(m)$11.37M$16.24M(m)-$12.68M
2021-03-31$3.47M(m)$10.02M$13.19M(m)-$9.72M
2020-09-30$2.83M(m)$7.22M$9.06M(m)-$6.22M
2020-06-30$3.07M(m)$6.33M$8.13M(m)-$5.04M
2020-03-31$3.23M(m)$7.89M$10.40M(m)-$6.95M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$12.63M$23.86M$26.00K-$20.80M
2025-06-30$800.00K$9.69M$14.15M$43.00K-$13.66M
2024-06-30(m)$19.48M$34.05M$89.00K-$29.88M
2023-06-30$7.32M$30.72M$41.32M(m)-$31.33M
2022-06-30$3.77M$29.83M$41.68M(m)-$37.33M
2021-06-30$7.02M$21.40M$29.43M(m)-$22.40M
2020-06-30$6.30M$14.23M$18.53M(m)-$11.98M

Revenue and expense 9 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-09-30$800.00K$800.00K$25.25M$40.75M-$74.00K-$38.44M
2024-09-30$3.50M$3.50M$28.35M$34.36M$0.00-$31.76M
2023-09-30$8.50M(m)$45.38M$62.01M(m)-$48.68M
2022-09-30$10.17M(m)$48.68M$65.96M(m)-$54.67M
2021-09-30$10.77M(m)$34.77M$47.70M(m)-$36.91M
2020-09-30$9.13M(m)$21.45M$27.59M(m)-$18.20M

Revenue and expense 12 month

Period endRevenueRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31$800.00K$800.00K$28.52M$49.25M-$350.00K-$45.35M
2024-12-31$3.50M$3.50M$32.11M$40.50M$13.00K-$36.57M
2023-12-31$9.16M(m)$59.65M$84.58M-$162.00K-$68.17M
2022-12-31$15.62M(m)$64.32M$86.52M$0.00-$68.77M
2021-12-31$30.98M(m)$47.11M$65.12M$0.00-$34.12M
2020-12-31$9.19M(m)$44.85M$53.71M(m)-$44.26M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
BioAtla, Inc. (BCAB)United States$0.058B-0.21
EXOZYMES INC. (EXOZ)United States$0.058B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioStem Technologies, Inc. (BSEM)United States$0.069B